PF 06835375

Drug Profile

PF 06835375

Alternative Names: PF-06835375

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antirheumatics; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 14 Nov 2017 Preclinical trials in Rheumatoid arthritis in USA (IV)
  • 14 Nov 2017 Preclinical trials in Systemic lupus erythematosus in USA (Parenteral)
  • 14 Nov 2017 Pfizer plans a phase I trial for Systemic lupus erythematosus and Rheumatoid arthritis (IV, SC) in December 2017 (NCT03334851)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top